| Omthera Pharmaceuticals, Inc. | $64 Million | Joint Bookrunner | Initial Public Offering | April 2013 |
| Cardiovascular Systems Inc. | $40 Million | Sole Bookrunner | Follow-On Offering | March 2013 |
| Cynosure, Inc. | $294 Million | Exclusive Financial Advisor | Acquisition of Palomar | March 2013 |
| OvaScience, Inc. | $35 Million | Lead Placement Agent | PIPE | March 2013 |
| Baxano, Inc. | Undisclosed | Exclusive Financial Advisor | Sale to TranS1 Inc. | March 2013 |
| Achillion Pharmaceuticals, Inc. | $142 Million | Joint Bookrunner | Follow-On Offering | February 2013 |
| Living Proof, Inc. | $30 Million | Exclusive Placement Agent | Private Placement | February 2013 |
| Celldex Therapeutics, Inc. | $104 Million | Joint Bookrunner | Follow-On Offering | February 2013 |
| KaloBios Pharmaceuticals, Inc. | $70 Million | Sole Bookrunner | Initial Public Offering | January 2013 |
| Trius Therapeutics | $34 Million | Joint Bookrunner | Follow-On Offering | January 2013 |
| Ultrasonix Medical Corporation | $83 Million | Exclusive Financial Advisor | Sale to Analogic Corp. | Announced Jan 2013 |
| Incline Therapeutics, Inc. | $390 Million | Exclusive Financial Advisor | Sale to The Medicines Co | January 2013 |
| Raptor Pharmaceutical Corp. | $50 Million | Financial Advisor | Structured Royalty Sale | December 2012 |
| DUSA Pharmaceuticals | $230 Million | Exclusive Financial Advisor | Sale to Sun Pharma | December 2012 |
| The Medicines Company | $105M + $10M Upfront | Exclusive Financial Advisor | Partnership with BMY | Announced Dec 2012 |
| Cynosure, Inc. | $75 Million | Sole Bookrunner | Follow-On Offering | November 2012 |
| Orexigen Therapeutics, Inc. | $61 Million | Joint Bookrunner | Follow-On Offering | October 2012 |
| Puma Biotechnology | $138 Million | Joint Bookrunner | Follow-On Offering | October 2012 |
| Globus Medical, Inc. | $115 Million | Joint Bookrunner | Initial Public Offering | August 2012 |
| Hyperion Therapeutics, Inc. | $58 Million | Joint Bookrunner | Initial Public Offering | July 2012 |
| Anthera Pharmaceuticals, Inc. | $38 Million | Joint Bookrunner | Follow-On Offering | July 2012 |
| Navigenics | Undisclosed | Exclusive Financial Advisor | Sale to Life Technologies | July 2012 |
| Unilife Corporation | $20 Million | Joint Bookrunner | Follow-On Offering | June 2012 |
| TESARO, Inc. | $87 Million | Joint Bookrunner | Initial Public Offering | June 2012 |
| Semprus BioSciences | $30 Million + Earnout | Exclusive Financial Advisor | Sale to Teleflex | June 2012 |
| Seaside Therapeutics | Undisclosed | Exclusive Financial Advisor | Collaboration with Roche | June 2012 |
| Cardiovascular Systems Inc. | $16 Million | Sole Bookrunner | Follow-On Offering | May 2012 |
| Transcept Pharmaceuticals, Inc. | $41 MIllion | Joint Bookrunner | Follow-On Offering | April 2012 |
| ArQule, Inc. | $60 Million | Joint Bookrunner | Follow-On Offering | April 2012 |
| OvaScience | $43 Million | Lead Placement Agent | Private Placement | April 2012 |
| OncoGenex Pharmaceuticals, Inc. | $57 Million | Joint Bookrunner | Follow-On Offering | March 2012 |
| Amicus Therapeutics, Inc. | $66 Million | Joint Bookrunner | Follow-On Offering | March 2012 |
| Array BioPharma | $60 Million | Joint Bookrunner | Follow-On Offering | February 2012 |
| Cempra, Inc. | $58 Million | Joint Bookrunner | Initial Public Offering | February 2012 |
| Verastem, Inc. | $63 Million | Joint Bookrunner | Initial Public Offering | January 2012 |
| Chelsea Therapeutics, Ltd. | $24 Million | Sole Bookrunner | Follow-On Offering | January 2012 |
| Vical Incorporated | $52 Million | Joint Bookrunner | Follow-On Offering | January 2012 |
